Helix Acquisition II today priced its upsized initial public offering of 16 million Class A shares at $10 each. The shares list on the Nasdaq and trade under the ticker symbol HLXB beginning today. The new SPAC expects the offering to close Feb. 13.
The original S-1 cited 10 million shares, later upsized to 15 million shares.
Formed by Cormorant Asset Management, Helix II intends to focus on the healthcare industry.
No warrants are included in the offering.
Cormorant has “indicated the interest” of buying 2.5 million shares as well as potentially investing $35 million in a private placement that would occur with the closing of a merger with the SPAC. There are no formal agreements in place for these possible investments. Cormorant is a life sciences-focused investment firm with over $2 billion AUM.
The SPAC intends to apply for a listing on the Nasdaq under the symbol HLXB.
Leerink Partners is sole bookrunning manager for the offering. Read more.
